SCHEMBL7807199

SCHEMBL7807199

CCCc1[nH]nc(-c2ccccc2)c1C(=O)Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.44
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
RAB9A P51151 2/20 0.42
HPGDS O60760 1/20 0.41
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
PDE10A Q9Y233 1/20 0.40
HPGD P15428 2/20 0.38
GRM5 P41594 1/20 0.38
PBRM1 Q86U86 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ATM Q13315 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GSK3A P49840 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4443384 0.87 HTT (0.42) RAB9AKDM4ENPC1ALDH1A1GAA
SCHEMBL7604984 0.83 PDE5A (0.42) PDE5APDE3BPDE3ARAB9AHPGDS
SCHEMBL15779014 0.76 HCAR2 (0.43) RAB9APDE10AADORA3MAPK1MAP2K4
SCHEMBL2374112 0.74 PDE5A (0.46) PDE5APDE3BPDE3ARAB9AHPGDS
SCHEMBL5063091 0.74 ALDH1A1 (0.46) RAB9AHPGDSHPGDKDM4EATM
SCHEMBL7514038 0.71 ABCC8 (0.54) RAB9AHPGDKDM4EATMNPSR1
SCHEMBL15779576 0.70 MAP2K4 (0.48) RAB9ANPC1SMN1; SMN2ADORA3LMNA
SCHEMBL4382163 0.67 RAB9A (0.49) RAB9AHPGDSPDE10AHPGDKDM4E
SCHEMBL17739710 0.67 GPR84 (0.41) PDE5APDE3BPDE3ARAB9AHPGDS
SCHEMBL28330637 0.67 MAPK14 (0.53) PDE5APDE3BPDE3ARAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1152759-A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-14 EP disclosed
WO-2000047194-A9 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR DIMENSIONAL PHARM INC (US) 2001-05-31 WO disclosed
WO-2000047194-A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed